Intravenous immunoglobulin treatment of neurological autoimmune diseases

被引:76
作者
Stangel, M
Hartung, HP
Marx, P
Gold, R
机构
[1] Univ Wurzburg, Dept Neurol, D-97080 Wurzburg, Germany
[2] Graz Univ, Dept Neurol, A-8036 Graz, Austria
[3] Univ Klinikum Benjamin Franklin, Dept Neurol, D-12200 Berlin, Germany
关键词
intravenous immunoglobulins; Mg; neurological autoimmune diseases; treatment; immunomodulation; immunotherapy;
D O I
10.1016/S0022-510X(97)00292-X
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Intravenous immunoglobulin (IVIg) has been widely used in neurological diseases during the last decade. The current indications of Mg in neurological diseases are reviewed and discussed on the basis of the available experimental data and clinical trials. Compared to other immunomodulating treatments used in neurological diseases, IVIg has only few side effects with a small risk of transmission of infectious agents. Good clinical evidence for the effectiveness is available for Guillain-Barre-Syndrome, chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. In conditions like myasthenia gravis and myositis favourable effects of Mg were reported, but future studies have to be awaited. For all other neurological conditions where IVIg has been administered, there is currently no support for the use of Mg other than in controlled trials. In conclusion, IVIg is a promising immunomodulary therapy that has been shown to be effective in some neurological autoimmune diseases. Routine use in neurological practice should be restricted to diseases for which a positive effect has been proven in controlled trials. For all other conditions no definite recommendations can presently be made. (C) 1998 Elsevier Science B.V.
引用
收藏
页码:203 / 214
页数:12
相关论文
共 167 条
[1]   OPEN CONTROLLED THERAPEUTIC TRIAL OF INTRAVENOUS IMMUNE GLOBULIN IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS [J].
ACHIRON, A ;
PRAS, E ;
GILAD, R ;
ZIV, I ;
MANDEL, M ;
GORDON, CR ;
NOY, S ;
SAROVAPINHAS, I ;
MELAMED, E .
ARCHIVES OF NEUROLOGY, 1992, 49 (12) :1233-1236
[2]   INTRAVENOUS IMMUNOGLOBULIN TREATMENT OF EXPERIMENTAL T-CELL-MEDIATED AUTOIMMUNE-DISEASE - UP-REGULATION OF T-CELL PROLIFERATION AND DOWN-REGULATION OF TUMOR-NECROSIS-FACTOR-ALPHA SECRETION [J].
ACHIRON, A ;
MARGALIT, R ;
HERSHKOVIZ, R ;
MARKOVITS, D ;
RESHEF, T ;
MELAMED, E ;
COHEN, IR ;
LIDER, O .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (02) :600-605
[3]  
Achiron A, 1996, J NEUROL, V243, P25
[4]   INCLUSION-BODY MYOSITIS - TREATMENT WITH INTRAVENOUS IMMUNOGLOBULIN [J].
AMATO, AA ;
BAROHN, RJ ;
JACKSON, CE ;
PAPPERT, EJ ;
SAHENK, Z ;
KISSEL, JT .
NEUROLOGY, 1994, 44 (08) :1516-1518
[5]  
ANDERSSON UG, 1993, IMMUNOLOGY, V79, P211
[6]  
[Anonymous], 1994, Ann Neurol, V35, P749
[7]  
[Anonymous], 1993, Lancet, V341, P586
[8]   EFFECTS OF REPEATED DOSES OF INTRAVENOUS IMMUNOGLOBULIN IN MYASTHENIA-GRAVIS [J].
ARSURA, EL ;
BICK, A ;
BRUNNER, NG ;
GROB, D .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1988, 295 (05) :438-443
[9]   HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN IN THE MANAGEMENT OF MYASTHENIA-GRAVIS [J].
ARSURA, EL ;
BICK, A ;
BRUNNER, NG ;
NAMBA, T ;
GROB, D .
ARCHIVES OF INTERNAL MEDICINE, 1986, 146 (07) :1365-1368
[10]   INTRAVENOUS IMMUNOGLOBULIN TREATMENT IN PATIENTS WITH MOTOR-NEURON SYNDROMES ASSOCIATED WITH ANTI-GM1 ANTIBODIES - A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY [J].
AZULAY, JP ;
BLIN, O ;
POUGET, J ;
BOUCRAUT, J ;
BILLETURC, F ;
CARLES, G ;
SERRATRICE, G .
NEUROLOGY, 1994, 44 (03) :429-432